Gerald Brock

Dr. Gerald Brock

Division of Urology, Western University Institution, London, ON N6A 3K7, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
ECErnest Pang Chan
Ernest Pang Chan
NPNahid Punjani
Nahid Punjani
JCJeffrey Douglas Campbell
Jeffrey Douglas Campbell
HAHaider Abed
Haider Abed
Gerald BrockGerald Brock
Gerald Brock
Introduction: Reoperations are necessary in approximately 30% of penile prostheses over 15 years following original implantation. Aim: To determine the most common indications for initial penile prosthesis reoperation at our institution and to describe technical alterations that have improved postoperative outcomes. Methods: A retrospective review of all patients who underwent penile prosthesis reoperation surgery at a single, high-volume Canadian center between 2006 and 2018 was performed. Patient demographic information, prosthetic device factors, and surgical complications were analyzed. Main Outcome Measure: The primary outcomes were the indications for and variables associated with initial penile prosthesis reoperation. Results: During the study period, 99 first-time penile prosthesis reoperations were performed out of 1,161 penile prosthesis procedures (Figure 1). This included 14 (14.1%) explants, 32 (32.3%) revisions, and 53 (53.5%) explant and reimplants. Indications for reoperation included 49 (49.5%) mechanical failures, 28 (28.3%) technical causes (such as correction of malposition or device herniation), and 12 (12.1%) procedures to treat chronic postoperative pain. Median follow-up was 78.5 months, and median time to reoperation was 46 months. Mechanical failures commonly occurred in the tubing (n = 13, 26.5%) and cylinders (n = 13, 26.5%). The most frequently repositioned component was the valve pump (n = 11, 39.3%). Infection-related indications for reoperation were uncommon (n = 10, 10.1%). Clinical Implications: More than a quarter of penile prosthesis reoperations may have been preventable with alterations in surgical technique, device positioning, and postoperative care. Strengths and Limitations: This study evaluates a range of indications for initial penile prosthesis reoperation performed by a high-volume single surgeon over a 12-year period. Limitations include the retrospective nature of the study, loss of patients to follow-up, and lack of etiological determinants of prosthesis failure. Conclusions: Reoperation for device repositioning and herniation was required for more than a quarter of the initial penile prosthesis implants. Modifications in surgical technique and perioperative care can help reduce the incidence of these technical causes for reoperation.

22 February 2023 in Endocrines
Verified
Journal Article
Open access
PDF file
MPMichael Pignanelli
Michael Pignanelli
NSNoah Stern
Noah Stern
Gerald BrockGerald Brock
Gerald Brock
Erectile physiology, in order to function normally, requires the complex coordination of endocrine, neurocognitive, neuromuscular and vascular mechanisms. Testosterone (T) influences male sexuality as well as penile erections at multiple levels, including a direct influence on the nitric oxide synthase (NOS)/cGMP/phosphodiesterase 5 pathway in the penis. However, the precise role of testosterone replacement (TRT) to “salvage” men with mixed ED failing phosphdiesterase-5 inhibitors (PDE5i) remains unclear. We conducted a scoping review identifying the rationale for TRT in ED failing PDE5i, and we critically discuss clinical trials that have examined TRT in the setting of PDE5i use. Overall, TRT replacement appears to be well tolerated and may enhance the response to PDE5i and quality of life, particularly for men with mixed ED, and particularly among men with very low levels of testosterone. However, most of the available literature examines concurrent TRT alone or simultaneous TRT + PDE5i usage, without necessarily selecting for PDE5i failure cases. The present studies are limited to heterogenous studies with small sample sizes, without an exact predominant etiologic factor causing ED. Furthermore, studies showing the most benefit are non-placebo-controlled trials; however, the correction of more profound hypogonadism may lead to an improved response to PDE5i. Stronger conclusions would require properly selected patient populations and larger placebo-controlled RCTs.

18 March 2021 in Canadian Urological Association Journal
Verified
Journal Article
Closed access
PDF file
Gerald BrockGerald Brock
Gerald Brock
FYFaysal A. Yafi
Faysal A. Yafi

29 August 2019 in Medical Sciences
Verified
Journal Article
Open access
PDF file
SSSamir Sami
Samir Sami
NSNoah Stern
Noah Stern
APAndrew Di Pierdomenico
Andrew Di Pierdomenico
BKBrandon Katz
Brandon Katz
Gerald BrockGerald Brock
Gerald Brock
Introduction: Optimizing erectile dysfunction (ED) remains a clinically significant endeavor as insufficient outcomes from oral, injectable and even surgical approaches to treatment remain less than ideal. In this report, we integrate evolving knowledge and provide an algorithmic approach for the clinician to fine-tune management. Methods: We performed a PubMed and Medline search of Erectile Dysfunction treatment optimization, enhanced patient efficacy for ED, and why men fail ED treatment. All relevant papers for the past two decades were reviewed. Results: Establishing the goals and objectives of the patient and partner while providing detailed instructions for treatment can minimize failures and create an environment that allows treatment optimization. A thorough work-up may identify reversible or contributing causes. We identified several areas where treatment of ED could be optimized. These include; management of associated medical conditions, lifestyle improvements, PDE5 inhibitor prescription strategies, management of hypogonadism and the initiation of intracavernosal injection therapy (ICI). Conclusions: In our view, once a man presents for help to the clinician, use of the simple strategies identified in this review to optimize the tolerability, safety and effectiveness of the selected treatment should result in enhanced patient and partner satisfaction, with improved outcomes.

10 July 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
TITaylor Incze
Taylor Incze
DPDalia Carmella Peres
Dalia Carmella Peres
SGSteven Guirguis
Steven Guirguis
SNSarah Neil-Sztramko
Sarah Neil-Sztramko
Jacqueline BenderJacqueline Bender
Jacqueline Bender
AMAndrew Matthew
Andrew Matthew
Sexual dysfunction is a prevalent and often under-addressed concern among prostate cancer survivors, significantly affecting quality of life for patients and their partners. The True North Sexual Health and Rehabilitation eClinic (SHAReClinic) is a virtual, biopsychosocial intervention developed to improve access to sexual health support for prostate cancer survivors and their partners. This study used a qualitative descriptive design to examine barriers and facilitators influencing the integration of SHAReClinic into oncology care across nine Canadian health care centres. Semi-structured interviews were conducted with 17 knowledge users, including health care providers and institutional leaders. Data were analyzed using a hybrid deductive–inductive thematic approach guided by the Consolidated Framework for Implementation Research (CFIR) 2.0. Participants described SHAReClinic as a much-needed resource, particularly in the absence of standardized sexual health pathways in oncology care. The virtual format was seen as accessible and well suited to addressing sensitive topics. However, limited funding, lack of institutional support, and workflow integration challenges emerged as primary barriers to implementation. Findings offer practical, theory-informed guidance for integrating SHAReClinic into oncology care and highlight key considerations for developing sustainable and scalable survivorship care models.

24 January 2022 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
SDSnir Dekalo
Snir Dekalo
Gerald BrockGerald Brock
Gerald Brock
Peyronie's disease (PD) is a wound-healing disorder often characterized by the triad of penile pain, curvature, and sexual dysfunction at initial presentation. Gur S Limin M Hellstrom WJG. Current status and new developments in Peyronie’s disease: Medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother. 2011; 12 : 931-944 Crossref PubMed Scopus (52) Google Scholar Peyronie's plaque pathogenesis remains incompletely elucidated but is thought to arise from abnormal extracellular matrix production. Studies suggest that PD prevalence is as high as 9% in the general population and higher in patients with diabetes or after radical prostatectomy. Herati AS Pastuszak AW. The genetic basis of Peyronie disease: A review. Sex Med Rev. 2016; 4 : 85-94 Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar A broad spectrum of treatments for PD are available including: surveillance, traction devices, intralesional injections and surgical interventions. Salonia A Bettocchi C Boeri L et al. European Association of Urology guidelines on sexual and reproductive health—2021 update: Male sexual dysfunction [Formula presented]. Eur Urol. 2021; 80 : 333-357 Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar There is an ever-growing interest in practical, low cost, state-of-the-art, minimally invasive approaches to manage this common problem.